Shots:
- Deep Apple & Novo have partnered to discover, develop, & commercialize oral small molecules targeting novel non-incretin GPCRs for cardiometabolic diseases, incl. obesity, using Deep Apple’s drug discovery tech
- Novo will gain exclusive global rights to develop, manufacture, & commercialize assets discovered & optimized by Deep Apple for ~$812M in upfront, research costs, & milestones, plus potential royalties; both will co-develop the research plan, with Novo taking over before IND-enabling studies
- Deep Apple’s tech uses ML-powered virtual screening with cryo-EM-based structural biology to accelerate lead discovery by capturing dynamic GPCR conformations & identifying novel binding pockets for docking with its virtual libraries
Ref: Prnewswire | Image: Prnewswire | Press Release
Related News:- Novo Nordisk Enters a ~$2.2B Deal with Septerna to Develop Oral Small Molecules for Cardiometabolic Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
